Zhitong Finance App News, Heyu-B (02256.HK) issued an announcement. On November 11, 2026, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical), a subsidiary of the company, announced that a CSF-1R small molecule inhibitor, Beijetmi® (English product name: PIMJETMI®, generic name: pimitinib hydrochloride capsules) has been approved by the US Food and Drug Administration (FDA) for the systematic treatment of adult patients with symptomatic tenosystem cytoma that may cause increased surgical excision function or serious complications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.